Aytu Biopharma, Inc (AYTU)

For the year ended 2026-06-30, Aytu Biopharma, Inc reported revenue of $57.57M. Revenue fell 13.3% from the prior annual period.

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Stock splits: 1-for-20, first reflected in a filing dated 2023-02-21. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.